Indication
In combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy.

Medicine details

Medicine name:
tofacitinib (Xeljanz)
SMC ID:
SMC2116
Pharmaceutical company
Pfizer Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full submission
Status
Advice due date:
14 January 2019
SMC meeting date:
04 December 2018
Patient group submission deadline:
05 November 2018